Studies aimed at reducing the detrimental effects of mTOR inhibition in ALS and other neurodegenerative diseases require a thorough investigation of its mechanisms and the metabolic pathways involved in its signaling. This evidence concerns the gene MTOR and amyotrophic lateral sclerosis.